Core Insights - Dianthus Therapeutics, Inc. is advancing its investigational monoclonal antibody, claseprubart, aimed at treating generalized Myasthenia Gravis (gMG) and will present Phase 2 trial results at the AANEM Annual Meeting [1][2] Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [5] - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team from the biotech and pharmaceutical sectors [5] Product Details - Claseprubart (DNTH103) is designed to selectively inhibit the active form of the C1s protein, targeting the classical complement pathway, which is significant in autoimmune disease pathology [3] - The drug incorporates YTE half-life extension technology for convenient subcutaneous self-administration [3] - Claseprubart has the potential to be a best-in-class treatment across various autoimmune disorders with high unmet medical needs [3] Upcoming Events - The results from the Phase 2 MaGic trial will be presented on October 29, 2025, during the MGFA Scientific Session [2] - A virtual industry forum titled "Upstream Targeting: Rethinking MG Treatment Through Active C1s Inhibition" will also take place on the same day, featuring an expert panel [2]

Core Insights - Dianthus Therapeutics has appointed Simon Read, Ph.D., to its Board of Directors, bringing over 30 years of biopharmaceutical leadership and expertise [1][2] - The company is focused on advancing its mid- and late-stage clinical programs, particularly the DNTH103 therapy for severe autoimmune diseases [2][3] - Lonnie Moulder will transition from the Board, having played a significant role in the company's growth from a private entity to a publicly traded company with three ongoing clinical trials [2] Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation antibody complement therapeutics aimed at treating severe autoimmune and inflammatory diseases [3] - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [3] Leadership Background - Dr. Read previously served as CEO and founder of Mariana Oncology until its acquisition by Novartis in 2024 and as Chief Scientific Officer at Ra Pharma until its acquisition by UCB in 2020 [1][2] - He has held leadership roles in R&D at major pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, and Roche/Genentech, contributing to the development of well-known immunology drugs [2] Clinical Development - The company is currently executing three clinical programs, with Phase 2 MaGic results for DNTH103 expected in September [3] - Dr. Read expressed confidence in the potential of DNTH103 as a best-in-class therapy for patients with severe neuromuscular conditions [3]

Core Insights - Dianthus Therapeutics has completed enrollment in the Phase 2 MaGic trial for DNTH103, targeting generalized Myasthenia Gravis (gMG) with a total of 65 patients enrolled, surpassing the initial target of 60 patients [2][3] - Initial top-line results from the MaGic trial are expected in September 2025, marking the first of three anticipated catalysts for DNTH103 by the end of 2026 [2][8] - DNTH103 is designed as a self-administered autoinjector, dosed once every two weeks, and aims to address significant unmet needs in the gMG market, which is estimated to exceed 100,000 patients in the U.S. [4][6] Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [10] - The company is building a neuromuscular franchise with DNTH103, which is also being evaluated in ongoing trials for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) [4][8] - DNTH103 is a potent monoclonal antibody that selectively inhibits the classical pathway by targeting the active form of the C1s protein, potentially offering a best-in-class treatment option [7][8] Clinical Trial Details - The MaGic trial is a global, randomized, double-blind, placebo-controlled Phase 2 study focusing on safety and tolerability as the primary endpoint, with secondary endpoints including Myasthenia Gravis Activities of Daily Living Scale (MG-ADL) and Quantitative Myasthenia Gravis (QMG) score assessments [3][5] - Following an initial loading dose, DNTH103 will be administered via subcutaneous injection every two weeks, with a treatment duration of 12 weeks and a 52-week open-label extension [5][6] Market Context - The gMG market in the U.S. is characterized by a significant number of patients seeking better treatment options, with approximately 85% of gMG patients having AChR autoantibody-driven disease [4][6] - Despite existing treatment options, there remains a substantial unmet need for therapies that provide continuous symptom control, lower infection risk, and more convenient dosing [4][6]